Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

What Was Tested

In this phase 4 trial, researchers set out to test Semaglutide for fat loss, obesity & body recomposition.

It had two arms (groups): Control Arm: GLP-1 Therapy Alone (active comparator) and Treatment Arm: GLP-1 Therapy + Exercise and Dietary Counseling (experimental).

Participants receive standard-of-care GLP-1 receptor agonist therapy (semaglutide) without additional exercise or dietary counseling.

Participants receive standard-of-care GLP-1 receptor agonist therapy (semaglutide) in combination with a 12-week structured exercise program and weekly individualized dietary counseling.

The registry classes the interventions as behavioral and drug.

Who Took Part

The registry lists 20 planned participants were the target.

It was open to people of any sex aged from 40 years up to 55 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age between 40 and 55 years. Body Mass Index (BMI) greater than 30. Android to gynoid fat ratio greater than 1.0. Currently eligible for GLP-1 therapy. No diagnosis of Type II diabetes.

The full record lists 6 inclusion and 7 exclusion criteria; among the exclusions: presence of abnormal ecg findings, including arrhythmias or ischemic changes; hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmhg or diastolic pressure exceeding 115 mmhg; borg rating of perceived exertion (rpe) greater than 19 during submaximal workloads.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Semaglutide group and the comparison group ran side by side rather than switching.

Nothing was hidden in this open-label Semaglutide study: the fat loss, obesity & body recomposition participants and staff both knew the treatment.

It started in 2026-04-06 with completion listed for 2026-06-29.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change in Skeletal Muscle Mass (time frame: Baseline to 12 weeks).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 20 people with fat loss, obesity & body recomposition.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.